Adalimumab for Rheumatoid Arthritis: Considerations for Reimbursement by Third-Party Payors

ISSN： 1173-8790

Source： Disease Management & Health Outcomes, Vol.12, Iss.1, 2004-01, pp. : 1-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Thiazolidinediones for Diabetes Mellitus: Considerations for Reimbursements by Third-Party Payors

By Andrew J. Palmer William J. Valentine Joshua A. Ray

Disease Management & Health Outcomes, Vol. 12, Iss. 6, 2004-01 ,pp. : 363-375

Adis International

Access to resources Recommend Favorite

Independent assessment by third-party certification bodies

By Tanner B.

Food Control, Vol. 11, Iss. 5, 2000-10 ,pp. : 415-417

Elsevier

Access to resources Recommend Favorite

Telemedicine from the Payor Perspective: Considerations for Reimbursement Decisions

By Whitten P. Kuwahara E.

Disease Management & Health Outcomes, Vol. 11, Iss. 5, 2003-01 ,pp. : 291-298

Adis International

Access to resources Recommend Favorite

FSH and rheumatoid arthritis

By Shapiro

Food and Chemical Toxicology, Vol. 34, Iss. 10, 1996-10 ,pp. : 1021-1021

Elsevier

Access to resources Recommend Favorite

Rheumatoid Arthritis: Diagnosis and Screening

By Leeb B.F. Weber K. Smolen J.S.

Disease Management & Health Outcomes, Vol. 4, Iss. 6, 1998-12 ,pp. : 315-324

Adis International

Access to resources Recommend Favorite